Bristol-Myers Presents 4-Year Data From Clinical Trials Of NULOJIX NASDAQ The company said that the results showed that the safety profile of NULOJIX through year 4 was consistent compared with results at year 3 with no new safety signals being identified, and that the renal function benefit versus cyclosporine was ... |
